Participated · Series A · Oct 2025

Valink Therapeutics engineers next-generation oncology therapeutics that combine bispecific antibody technology with antibody-drug conjugates to improve efficacy, safety, and precision. Its proprietary discovery platform and V-gate™ approach expand the design space for bsADCs, enabling fine-tuned target control and an improved therapeutic index compared with current ADC technologies. Beyond bsADCs, the company is building a suite of multispecific or multifunctional ADCs and multivalent agonists to address additional therapeutic needs. Valink is advancing two first-in-class oncology programs for solid tumors, including colorectal cancer, which are now moving toward preclinical development. Proceeds from recent financing will fund this pipeline progression and further platform development. The company operates from its headquarters in Cambridge, Massachusetts, with R&D facilities in the United Kingdom.

Participated · Series A · Oct 2025

Trogenix is a biotechnology company focused on creating “one-and-done” treatments for aggressive solid tumours through its Odysseus platform. The platform combines genomics, oncology, immunotherapy and gene therapy, using AAV vectors to deliver proprietary Synthetic Super-Enhancers (SSEs) directly into tumour cells while evading immune detection. These SSEs precisely regulate gene expression to expose cancer cells to the immune system and trigger tumour cell death. If residual tumour cells persist, the approach acts as a ‘Trojan horse’ to counter recurrence. Founded by life-science investor 4BIO, the company aims to advance a pipeline of potentially curative therapies toward clinical trials. Trogenix is led by CEO Ken Macnamara and is headquartered in Edinburgh, Scotland. The new capital positions the company to accelerate pre-clinical research and move multiple candidates into the clinic.

Participated · Seed · Dec 2024

Proton is developing a small device designed to be inserted just below the skin to continuously monitor potassium levels and pair with a smartphone app for patient alerts. A clinician dashboard is planned so care teams can view potassium trends and fine-tune therapies, potentially reducing in-clinic potassium testing, time, and costs. The company targets patients with chronic kidney disease and those at risk of heart failure, where potassium imbalances can be life‑threatening. Clinical trials are underway for the product, which Proton says is due to launch in 2025. The founders are CEO Sahan Ranamukhaarachchi (based in Vancouver) and CSO Victor Cadarso (based in Melbourne); the company has a commercial HQ in Canada and an R&D subsidiary in Melbourne, Australia. Proton positions its approach against other emerging potassium-monitoring firms and claims greater scalability, usability, and clinical impact.

Participated · Seed · May 2024

CatenaBio is a UC Berkeley spinout from the labs of Jennifer Doudna and Matt Francis focused on creating therapeutic structures that enable multiple kinds of payloads of any size and complexity. Its initial product area is first-in-class "multi payload conjugates" (MPCs™). The company positions its approach as rapidly escalating the effectiveness and usefulness of antibody-drug conjugates and enabling targeted combination therapies beyond current clinical options. CatenaBio plans to accelerate development of its lead asset, launch scale-up activities with leading CROs, and continue supporting business-development partnerships with biotech and pharma collaborators. The recently closed seed extension will extend runway to generate additional compelling data to support a Series A later this year. CEO Marco Lobba, Ph.D., said the funds will enable accelerated buildup of the MPC pipeline.

Participated · Series A · Apr 2024

Rubedo Life Sciences develops novel small-molecule therapies engineered to selectively target various types of senescent cells using its ALEMBIC™ drug discovery platform. Its lead candidate, RLS-1496, is being advanced into Phase 1 studies for chronic atopic dermatitis and chronic psoriasis. The company is also developing programs targeting senescent cells in pulmonary diseases, including a program for idiopathic pulmonary fibrosis (IPF) that received a substantial CIRM grant last year. Rubedo’s pipeline targets multiple therapeutic areas tied to aging biology, such as pulmonary, dermatological, oncological, neurodegenerative and fibrotic disorders. The company is led by CEO & Co‑Founder Marco Quarta with Ali Siam as Chief Business Officer and is based in Sunnyvale, California. Financially, Rubedo recently closed a $40M Series A to fund its clinical and preclinical programs. Rubedo Life Sciences develops novel senolytic small‑molecule prodrugs via its proprietary ALEMBIC drug discovery platform to selectively target pathologic senescent cells that drive age‑related diseases. The company is advancing a pharmacological regenerative program for idiopathic pulmonary fibrosis (IPF), aiming to characterize senescent lung stem and progenitor cells and to screen a library of senolytic prodrugs on IPF primary cells. Rubedo plans to nominate a lead senolytic development candidate and to develop a clinical study using a humanized IPF model. The program is supported by a $1.45M award from the California Institute for Regenerative Medicine (CIRM). Rubedo has partnered with Cedars‑Sinai for the IPF research, with Cory Hogaboam, PhD, leading the Cedars‑Sinai effort. The company is based in Sunnyvale, CA, and is led by CEO and co‑founder Marco Quarta, PhD. Rubedo Life Sciences develops novel small-molecule therapies engineered to selectively target senescent, pro-inflammatory and pro-fibrotic cell populations using its proprietary ALEMBIC™ drug discovery platform. The company’s lead programs focus on respiratory diseases with high unmet need, including idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Rubedo also has preclinical candidates in oncology and plans to pursue programs in neurodegenerative conditions, skeletal muscle disorders and other age-related diseases. The company plans to advance several compounds into IND-enabling studies in pulmonary diseases starting next year. Rubedo is based in Sunnyvale, California. It recently closed a seed financing to accelerate development of its clinical pipeline.